Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.fivestarequities.com/ and get exclusive access to our numerous stock reports.
Astex Pharmaceuticals, Inc. (NASDAQ: ASTX) shares soared 24.45 percent to close at $6.82 a share Wednesday. The stock traded between $6.26 and $6.99 on volume of 14.43 million shares traded. The company reported positive data from an ongoing phase 2 of SGI-110 in patients with AML and MDS. Shares of Astex Pharmaceuticals have gained over 130 percent year-to-date.
Get more information on Astex Pharmaceuticals and free access to the in-depth equity report at:
AeroVironment, Inc. (NASDAQ: AVAV) shares declined 0.68 percent to close at $22.02 a share Wednesday. The stock traded between $20.78 and $22.36 on volume of 701,937 shares traded. The company reported revenues were $44.1 million for the first quarter of fiscal 2014, compared to $58.7 million a year ago. Shares of AeroVironment have fallen approximately 35.0 percent year-to-date.
Get more information on AeroVironment and free access to the in-depth equity report at:
Endo Health Solutions Inc. (NASDAQ: ENDP) shares increased 3.80 percent to close at $40.67 a share Wednesday. The stock traded between $39.22 and $40.79 on volume of 2.63 million shares traded. The company announced it has acquired Boca Pharmacal, a specialty generics company, for $225 million in cash. Shares of Endo Health Solutions have gained approximately 55.0 percent year-to-date.
Get more information on Endo Health Solutions and free access to the in-depth equity report at:
Zale Corporation (NYSE: ZLC) shares soared 29.80 percent to close at $11.63 a share Wednesday. The stock traded between $10.13 and $11.69 on volume of 7.22 million shares traded. The company reported net earnings were $10.0 million for the fiscal year 2013, compared to a net loss of $27.0 million a year ago. Shares of Zale have gained approximately 180.0 percent year-to-date.
Get more information on Zale and free access to the in-depth equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Five Star Equities
Leave a comment...